Coronavirus / COVID

Available literature on thrombosis occurrence in COVID-19 patients focuses on hospitalized cases. A new study sheds light on the incidence of thromboembolism in less severe cases of disease,

The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.

A new study from the CDC underscores the importance of staying up to date on COVID-19 vaccines and boosters, showing a rapid drop in vaccine effectiveness among children during the Omicron wave that increased with booster doses.

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization (EUA).

At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.

In hospitalized COVID-19 patients, remdesivir stewardship reduced hospital length of stay and therapy duration.

The CDC’s COVID-19 booster dose recommendation for children 5 and older comes a few days after the FDA’s authorization

Leveraging antimicrobial stewardship programs was crucial to ensure COVID-19 hospital inpatients received monoclonal antibody therapy quickly and safely.

To reduce the risk of antimicrobial resistance, rapid laboratory diagnostics are needed to identify the pathogens in hospital patients with COVID-19 and sepsis.

A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.

Public health and school officials need to consider strategies now.

Data on hospitalizations of children during the pandemic highlighted the seriousness of MIS-C, particularly in children of color.

A new study in the United Kingdom provided evidence in support of a fourth dose of COVID-19 vaccines, showing a strong boost in immunity.

A third, “booster,” dose of the Pfizer-BioNTech COVID-19 vaccine is now FDA-approved for children 5-11 years old.

As we recently surpassed the 2-year mark of the pandemic, the May issue reflects on lessons learned thus far.

This is the first test authorized for all 3 viruses and is over the counter.

Though it failed to meet its primary study endpoints, post hoc analysis of SNG001 showed the inhalable reduced the risk of severe COVID-19 disease and death in high-risk patients.

Stage 2/3 trials are underway to test the efficacy of J08, a potent monoclonal antibody, to prevent and treat current and future COVID-19 variants.

Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.

COVID-19 patients who do not speak English faced worse hospital outcomes during the first wave of the pandemic.

A study of pregnant women positive for COVID-19 at delivery found no evidence of vertical transmission, but increased gastrointestinal problems in their newborn infants.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

At 1 year after COVID-19 infection, children’s neutralizing antibodies only differed by vaccination status.

The federal agency authorized the therapy as a standalone treatment via a revised EUA in July of last year.

Despite a significantly slower than expected COVID-19 vaccine rollout, Novavax reports early 2022 as its first profitable quarter.

The higher the gestational age when pregnant women received a COVID-19 vaccine, the higher the serological titers at birth.

Children living with HIV had a similar immune response to mRNA COVID-19 vaccination as children without HIV.

Investigators examined whether rapid antigen tests were less sensitive to variants of concern. Though the tests detected Omicron, all but 1 were less effective in detecting the Delta variant.

Using monoclonal antibodies as post-exposure prophylaxis could be a cost-effective approach to battling COVID-19 in scenarios that include high transmission of susceptible variants, a new study suggests.

JAMA study reveals use of dexamethasone and others in non-hospitalized patients with mild to moderate illness.